Zejula approved for certain female cancers

March 28, 2017

(HealthDay)—Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk in response to platinum-based chemotherapy.

Citing the National Cancer Institute, the FDA said in a news release that more than 22,000 women are expected to be diagnosed with these cancers this year, and more than 14,000 will die of these diseases.

Zejula is designed to block an enzyme involved in repairing damaged DNA. The thought is that by blocking this enzyme, cancer cells would die and slow down or stop tumor growth, the FDA said.

The drug was evaluated in clinical studies involving 553 people with any of these recurring cancers who had had their tumors shrunk by at least two doses of . The average progression-free survival of certain women given Zejula was 21 months, compared with 5.5 months among women who took a placebo, the FDA said.

The most common side effects were low levels of , or blood platelets; heart palpitations, nausea, constipation, abdominal pain, and mucous membrane inflammation.

More serious adverse reactions could include high blood pressure and bone marrow problems, the FDA said.

Approval of Zejula was granted to Tesaro Inc.

Explore further: FDA clears ovarian cancer drug for hard-to-treat disease

More information: Visit the FDA to learn more.

Related Stories

FDA clears ovarian cancer drug for hard-to-treat disease

December 19, 2016
U.S. health officials have approved a new option for some women battling ovarian cancer: a drug that targets a genetic mutation seen in a subset of hard-to-treat tumors.

New treatment approved for soft-tissue cancers

October 19, 2016
(HealthDay)—Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft-tissue sarcomas, cancers that develop in areas such as the muscles, fat, blood vessels and tendons.

Bavencio approved for rare skin cancer

March 23, 2017
(HealthDay)—Bavencio (avelumab) has been approved by the U.S. Food and Drug Administration to treat a rare but aggressive form of skin cancer called Merkel cell carcinoma (MCC), the agency said Thursday in a news release.

Lonsurf approved for advanced colon cancer

September 23, 2015
(HealthDay)—The combination pill Lonsurf (trifluridine and tipiracil) has been approved by the U.S. Food and Drug Administration to treat advanced colon cancer for people who aren't responding to other treatments, the agency ...

Xermelo approved for tumor-related diarrhea

March 1, 2017
(HealthDay)—Xermelo (telotristat ethyl) tablets have been approved by the U.S. Food and Drug Administration to treat adults with carcinoid syndrome diarrhea, one of a collection of symptoms related to rare carcinoid tumors.

New drug approved for lack of certain white blood cells

August 30, 2012
(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

Recommended for you

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.